Akari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation

Akari is currently conducting a registrational Phase II study of nomacopan in pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy.